One of the most common concerns about GLP-1 medications is muscle loss. The worry is straightforward: if you lose weight quickly, won't you lose muscle along with fat? And if you do, doesn't that make you worse off metabolically in the long run? The research on this question is more nuanced — and more encouraging — than headlines suggest.
What the Clinical Trials Show
In the landmark STEP 1 trial for semaglutide (Wegovy), participants lost an average of 15% of body weight, and roughly 39% of that weight loss was lean body mass. That 39% figure has been widely cited as alarming. But context matters.
First, lean body mass is not the same thing as skeletal muscle. Lean body mass includes water, bone, connective tissue, and organ mass — particularly the liver, which shrinks significantly with weight loss. A 2026 study published in Cell Reports Medicine found that among lean tissues, liver mass loss exceeded muscle mass loss with GLP-1 treatment. UC Davis exercise physiologist Keith Baar put it directly: the reported 40% lean mass loss is substantially driven by liver changes, and actual skeletal muscle loss is closer to 15–25% of total weight lost.
Second, this ratio is comparable to what happens with any form of caloric restriction. When you lose weight through dieting alone, approximately 20–40% of weight lost is lean mass. GLP-1 medications do not appear to cause disproportionate muscle loss compared to calorie-equivalent weight loss through diet.
The Newer Research Is More Reassuring
A large genetic analysis from the University of Hong Kong, studying over 800,000 individuals, confirmed that while both lean and fat mass are reduced with GLP-1 treatment, fat loss substantially exceeds lean mass loss, resulting in an improved overall body composition. The key finding: the ratio of fat loss to lean mass loss favors fat, meaning your body composition actually gets better even though you lose some muscle.
A 2026 Cell Reports Medicine study in both mice and humans found that while absolute muscle mass decreased with GLP-1 treatment, relative muscle mass and strength actually improved — meaning patients had more muscle per pound of body weight than before, and their physical performance (measured by running ability in animal models) was better.
Who's Most at Risk
Muscle loss is a greater concern for older adults (over 65), people with low baseline muscle mass, patients who are sedentary, and those who don't consume adequate protein during treatment. For these groups, the risk of sarcopenia (clinically significant muscle loss affecting function and independence) deserves specific attention and mitigation.
How to Protect Your Muscle
The evidence-based strategies for preserving muscle during GLP-1 treatment are well-established. Resistance training two to three times per week is the single most important intervention — it directly stimulates muscle protein synthesis and counteracts the muscle-wasting signal from caloric deficit. Protein intake of at least 1.0–1.2 grams per kilogram of body weight daily (and up to 1.6 g/kg for actively training individuals) provides the building blocks for muscle maintenance. Adequate sleep supports muscle repair, and aerobic exercise (150+ minutes per week of moderate intensity) supports cardiovascular and metabolic health alongside the strength work.
The Bottom Line
Some muscle loss during weight loss is inevitable — with or without medication. GLP-1 medications don't cause worse muscle loss than dieting alone. The early "40% lean mass loss" headlines were misleading because they conflated liver mass and water with skeletal muscle.
The newer data is encouraging: body composition improves with treatment, relative muscle mass increases, and the muscle loss that does occur can be substantially offset with resistance training and adequate protein. Talk to your doctor about an exercise and nutrition plan that supports your treatment.